Osteoporosis

Latest

Risks Associated With Denosumab Discontinuation

Risks Associated With Denosumab Discontinuation

Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.

FDA Requests Additional Data in Romosozumab Biologics License Application

FDA Requests Additional Data in Romosozumab Biologics License Application

The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.

Does Sedative Use Increase Repeat Fall Risk?

Does Sedative Use Increase Repeat Fall Risk?

Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.

ACP: Updated Osteoporosis Treatment Guidelines

ACP: Updated Osteoporosis Treatment Guidelines

An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.

Osteoporosis, Fracture Risk Elevated With Tuberculosis

Osteoporosis, Fracture Risk Elevated With Tuberculosis

Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.

Benefits of Osteoporosis Pharmacotherapy Misunderstood Among Older Women

Benefits of Osteoporosis Pharmacotherapy Misunderstood Among Older Women

Eighty-four percent of survey respondents did not undergo osteoporosis pharmacotherapy following an osteoporosis-related fracture.

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis

Tymlos approval was based on the results of the ACTIVE and ACTIVExtension trials.

Long-Term Safety of Denosumab in Postmenopausal Osteoperosis

Long-Term Safety of Denosumab in Postmenopausal Osteoperosis

The most common adverse events associated with long-term denosumab use were back, musculoskeletal, or extremity pain, hypercholesterolemia, and cystis.

Osteoporosis Care Quality Most Consistently Predicted By Primary Care

Osteoporosis Care Quality Most Consistently Predicted By Primary Care

The most important predictor for use of osteoporosis care was receiving primary care services within 6 months following hip fracture.

Sign Up for Free e-Newsletters

CME Focus